The FLOW results showed that the percentage of CTLA-4+PD-1+ on CD4+ cells (Upper, Figure 5D) and FoxoP3+CD25+ on CD4+ immunosuppressive Tregs (Lower, Figure 5D) were lower in tumor allografts from combined treatment compared to other single treatments. This evidence concerns the gene PDCD1 and neoplasm.